Fact checked byRichard Smith

Read more

March 04, 2024
3 min read
Save

FDA to allow limited claims that eating yogurt may reduce risk for type 2 diabetes

Fact checked byRichard Smith
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA said it will permit the use of two limited health claims that eating yogurt may reduce the risk for type 2 diabetes, according to a press release.

In a letter of enforcement discretion released March 1, the FDA responded to a health claim petition submitted on behalf of Danone North America. The petition asked the FDA to review a qualified health claim between the consumption of yogurt and reduced risk for type 2 diabetes for all types of yogurts that meet the FDA’s standard of identity. The petition also stated that scientific evidence supports the health effects of yogurt as a food rather than anything related to any single nutrient or compound.

Generic FDA News infographic
On March 1, the FDA stated it intends to consider exercising enforcement discretion for two qualified health claims that eating yogurt may reduce the risk for developing type 2 diabetes.

After a review of the petition and the data presented within it, the FDA stated it intends to consider exercising enforcement discretion for two qualified health claims between yogurt and a reduced risk for type 2 diabetes. The two qualified health claims are:

  • Eating yogurt regularly, at least two cups (three servings) per week, may reduce the risk for type 2 diabetes. FDA has concluded that there is limited information supporting this claim.
  • Eating yogurt regularly, at least two cups (three servings) per week, may reduce the risk for type 2 diabetes according to limited scientific evidence.

Some studies find yogurt lowers type 2 diabetes risk

According to the FDA’s response letter, Danone North America’s petition cited 117 publications as evidence to support its proposed claims, including 50 observational studies; 33 human intervention studies; 11 reviews; eight meta-analyses; nine publications related to nutrition, dietary intake and validation of dietary assessment tools; three reports; two position statement; and one methodological study.

The FDA based its response on a review of 28 observational studies that reported on the relationship between yogurt consumption and type 2 diabetes. Most of the studies assessed yogurt intake through a food frequency questionnaire. Endpoints consisted of incidence of type 2 diabetes or validated endpoints for type 2 diabetes such as fasting blood glucose alone or as a component of metabolic syndrome, impaired glucose metabolism, HbA1c and prediabetes alone or in combination with insulin resistance.

Of the studies the agency reviewed, nine were described as being of a high methodological quality. Among those nine studies, six examined associations between yogurt intake and type 2 diabetes risk. A reduced risk for type 2 diabetes with yogurt consumption was found among three prospective cohort studies from Spain as well as from the Nurses’ Health Study and the Women’s Health Study cohorts in the U.S. However, data from the Nurses’ Health Study II and the Health Professionals Follow-up Study cohorts found no link between eating yogurt and type 2 diabetes risk. There were three high-quality studies that assessed the effect of change in yogurt intake on risk for type 2 diabetes. The FDA stated the findings among those studies were inconsistent.

No link observed in most moderate-quality studies

The remaining 19 studies included in the review were deemed to be moderate in quality. The FDA said findings were inconsistent among four cross-sectional studies. Of 10 moderate-quality studies that assessed incidence of type 2 diabetes, four found yogurt reduce the risk for type 2 diabetes. No associations were observed between yogurt and endpoints of type 2 diabetes among six moderate-quality observational studies.

The FDA stated scientific conclusions could not be drawn from the intervention studies included in the petition as they “were not sufficiently controlled to provide useful information for assessment of a health claim.” The FDA also did not include the human intervention studies, reviews, meta-analyses and other background reports in its review.

“Based on the findings of these 28 observational studies, FDA concludes that there is some credible evidence supporting a relationship between yogurt intake and reduced risk of type 2 diabetes,” the FDA’s response letter stated. “As noted in the petition, the credible scientific evidence found a statistically significant association between risk reduction of type 2 diabetes and yogurt as a food, rather than any single nutrient or compound in yogurt, and irrespective of fat or sugar content. However, this evidence is based exclusively on observational studies which, despite controlling for relevant covariates, cannot exclude residual confounding due to unknown or unmeasured confounders. Consequently, observational studies measure associations instead of a cause-and-effect relationship between a substance and disease. Furthermore, the study findings were inconsistent. Most of the statistically significant associations between yogurt intake and reduced risk of type 2 diabetes were observed among the high methodological quality studies; however, most of the moderate-quality studies did not observe a statistically significant association.”

Reference:

FDA. RE: Petition for a qualified health claim for yogurt and reduced risk of type 2 diabetes mellitus (Docket No. FDA-2019-P-1594). Available at: https://www.fda.gov/media/176608/download?attachment. Published March 1, 2024. Accessed March 4, 2024.